Financials

Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
-21.65
Price to sales ratio
4.47

Related tickers

#NamePrice24h %7d %1M %1Y %Market CapLast 7 Days
782
ICLR
ICON plc - Ordinary Shares
170.02 USD+0.18%-0.46%+2.85%-3.75%13.02 B USD
960
QGEN
Qiagen N.V. Common Shares
43.10 USD-1.40%-1.96%+1.77%-9.03%9.35 B USD
1237
RDNT
RadNet, Inc. - Common Stock
74.61 USD-1.00%-3.08%+15.05%-10.55%5.87 B USD
1290
SHC
Sotera Health Company - Common Stock
19.27 USD-1.08%-1.08%+8.14%+14.29%5.50 B USD

Frequently asked questions about Twist Bioscience Corporation Common Stock

What is the Twist Bioscience Corporation Common Stock stock price today?

The current price of Twist Bioscience Corporation Common Stock (TWST) is 141.38. Over the past 24 hours, the stock has changed by -7.66%. Follow the TWST chart for real-time price dynamics.

What is the stock ticker of Twist Bioscience Corporation Common Stock?

Twist Bioscience Corporation Common Stock trades under the ticker TWST. Tickers can differ by exchange, so always check the exchange and instrument details before trading.

Is Twist Bioscience Corporation Common Stock stock going up?

TWST has changed by -2.50% over the last week, +73.26% over the last month, and +428.52% over the last year. Review the chart to see whether the current move is part of a broader trend.

What is the market capitalization of Twist Bioscience Corporation Common Stock?

Twist Bioscience Corporation Common Stock currently has a market capitalization of 8.87 B. Market capitalization reflects the total market value of a company's outstanding shares and is commonly used to compare companies by size.

What were Twist Bioscience Corporation Common Stock earnings last quarter?

Last quarter, Twist Bioscience Corporation Common Stock reported earnings of -0.56 per share. Earnings per share is one of the key metrics investors use to evaluate a company's profitability and financial performance.

What was Twist Bioscience Corporation Common Stock revenue for the last quarter?

Twist Bioscience Corporation Common Stock reported quarterly revenue of 118.38 M. Revenue is one of the main indicators used to evaluate the company's business growth and operating scale.

What was Twist Bioscience Corporation Common Stock net income for the last quarter?

Twist Bioscience Corporation Common Stock reported net income of -35.05 M for the last quarter. The previous quarter showed -44.02 M, which means net income changed by +20.38%.

How many employees does Twist Bioscience Corporation Common Stock have?

As of the latest available data, Twist Bioscience Corporation Common Stock has 979 employees. Workforce size can provide additional context about the company's scale and operations.

What is Twist Bioscience Corporation Common Stock EBITDA?

Twist Bioscience Corporation Common Stock EBITDA is -29.5 M, and its EBITDA margin is -24.92%. EBITDA is commonly used to evaluate operating performance before interest, taxes, depreciation, and amortization.

How can I buy Twist Bioscience Corporation Common Stock stock?

You can buy Twist Bioscience Corporation Common Stock (TWST) through a broker that provides access to the relevant stock exchange. Before trading, check commissions, execution conditions, account type, and whether the stock fits your investment plan.

Should I invest in Twist Bioscience Corporation Common Stock stock?

Investing in Twist Bioscience Corporation Common Stock requires reviewing its financial statements, valuation, earnings outlook, news, technical picture, and market risks. Use the TWST chart and related analysis on metatrader.com as part of your research.

Twist Bioscience Corporation - Common Stock

Twist Bioscience is a public biotechnology company based in South San Francisco that manufactures synthetic DNA and DNA products for customers in a wide range of industries. Twist was founded in 2013 by Emily Leproust, Bill Banyai, and Bill Peck. The company was represented by Leproust at a March 2021 tabletop exercise at the Munich Security Conference simulating an outbreak of weaponized monkeypox. In May 2021, Twist Bioscience and Genome Project-Write launched a new CAD platform for whole genome design. The CAD will automate workflows to enable collaborative efforts critical for scale-up from designing plasmids to megabases across entire genomes.

News